Skip to content

Deferring hepatitis C treatment can lead to liver cancer and death, despite cure

Cindy Zahnd presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

Progression to severe fibrosis or cirrhosis is common among baby boomers with hepatitis C in the US

Monina Klevens presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection

David Wyles and Susanna Naggie presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

Clinicians report two acute HCV infections in Kaiser San Francisco PrEP programme

A more personalised approach to hepatitis C treatment may improve adherence and completion rates

AbbVie next-generation hepatitis C drugs look promising in early studies

HCV prevention campaigns need to focus on reducing frequency of injecting drug use involving sharing of equipment

Experimental siRNA therapy lowers HBsAg levels in people with hepatitis B

Entecavir and tenofovir work well for people with drug-resistant hepatitis B virus